Imagine a health app that doesn't just look at one illness, but sees how all your health issues interact like a complex puzzle. It uses a massive library of European patient data to predict when a heart rhythm problem might lead to other complications. This helps doctors step in early to stop a health decline before it happens.
Healthcare systems currently treat chronic diseases in isolation, failing to see how multiple conditions interact. This leads to missed early intervention opportunities, higher hospitalization rates, and increased mortality.
A multinational harmonized data platform and an AI tool that predicts individual risk of comorbidities using clinical, imaging, and lifestyle data.
If you are a diagnostics developer dealing with fragmented patient data — this project developed a harmonized digital platform that integrates clinical, imaging, and lifestyle data to predict individual risk of worsening comorbidities.
If you are a drug manufacturer dealing with low patient adherence to treatment regimens — this project developed an AI tool that improves how patients follow medication plans by providing personalized risk assessments.
If you are a hospital network dealing with high rates of avoidable hospitalizations — this project developed a predictive system to identify high-risk atrial fibrillation patients for earlier intervention.
Based on available project data, no pricing or cost information is provided as this is a research and innovation action.
The project uses a multinational platform across 10 countries, suggesting the infrastructure is designed for large-scale European healthcare integration.
Based on available project data, specific licensing terms are not listed, though the project includes 6 industry partners who may hold joint IP.
The project includes a dedicated work package (WP2) to address ethical and legal requirements for trustworthy AI and patient data use.
The project runs from 2023-11-01 to 2028-10-31, with clinical trials and implementation occurring in the later stages (WP7 and WP8).
The consortium is well-balanced for commercialization, featuring a 33% industry ratio with 6 companies, including 5 SMEs. With 11 universities across 10 countries, the project combines deep academic research with practical industrial application, reducing the gap between lab development and market entry.
Contact the Universita degli Studi di Modena e Reggio Emilia
Contact us to explore licensing opportunities for the AI risk-assessment platform.
